All In Biotech

Drug Trial Radar · NCT03468426

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With Ezabenlimab to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer and in Other Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

252

Actual

Start

Jul 5, 2018

Primary completion

Jul 31, 2024

Study completion Sep 12, 2024

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Mar 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The second part was open also to adults with other types of advanced cancer of the lung, brain, skin, and liver. After early encouraging results, more people with liver cancer can now take part in the study. The participants get a combination of two medicines called BI 836880 and ezabenlimab. BI 836880 is a type of an antibody that blocks new blood vessel formation. New blood vessels are needed by the tumour to continue growing. Ezabenlimab is an antibody that may help the immune system fight cancer (immune checkpoint inhibitor). The purpose of the first part of the study was to find out the highest dose of the BI 836880 that the participants can tolerate in combination with BI 754091. After the best dose of BI 836880 for the combination with ezabenlimab was found, it is used in the second part of the study. The purpose of the second part is to see whether the combination of BI 836880 and BI 754091 is able to make tumours shrink. The participants are in the study as long as they benefit from and can tolerate treatment. During this time, they get infusions of BI 836880 and ezabenlimab every 3 weeks. The doctors also regularly check the general health of the participants.

Conditions

  • Non-squamous, Non-Small-Cell Lung Cancer
  • Neoplasms

Interventions

  • BI 836880Drug

    BI 836880 as an intravenous infusion on day 1 of each 3-week cycle.

  • EzabenlimabDrug

    240 mg Ezabenlimab (BI 754091) as an intravenous infusion on day 1 of each 3-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - Number of Patients With Dose Limiting Toxicity (DLT) Within the First Cycle of TreatmentTime frame: The first treatment cycle, up to 21 days.
  2. Part 2 - Objective Response (OR)Time frame: Up to 778 days.

Locations

43 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • Winship Cancer Institute

    Atlanta, Georgia

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Royal North Shore Hospital-St Leonards-20807

    St Leonards, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Peninsula & South Eastern Oncology Group

    Frankston, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • CTR Georges-François Leclerc

    Dijon, France

  • HOP Timone

    Marseille, France

  • INS Curie

    Paris, France

  • CTR Eugène Marquis

    Rennes, France

  • HOP Nord Laennec

    Saint-Herblain, France

  • HOP Civil

    Strasbourg, France

  • Universitätsklinikum Augsburg

    Augsburg, Germany

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Germany

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, Germany

  • Universitätsklinikum Regensburg

    Regensburg, Germany

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • University Clinical Center, Gdansk

    Gdansk, Poland

  • Mandziuk Slawomir Specialist Medical Practice

    Lublin, Poland

  • European Health Center Otwock

    Otwock, Poland

  • MED POLONIA SP Z O O, Clinical Trials Department,Poznan

    Poznan, Poland

  • Dom Lekarski S.A.

    Szczecin, Poland

  • JSC "Group of Companies "Medsi"

    Moscow, Russia

  • SBHI "Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncological)"

    Saint Petersburg, Russia

  • State Budget Healthcare Institution "Volgograd Regional Clinical Oncology Dispensary"

    Volgograd, Russia

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Hospital Universitari Vall D Hebron

    Barcelona, Spain

  • Hospital Clínic de Barcelona

    Barcelona, Spain

  • Hospital Clinico Universitario De Valencia

    Valencia, Spain

  • NCKUH

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council

    Dnipropetrovks, Ukraine

  • Kyiv City Clinical Oncological Center

    Kyiv, Ukraine

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.